Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance

Cronos Group IncTrade
Invesco S&P 500 Momentum ETFTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.03B), while Invesco S&P 500 Momentum ETF trades at $153.8. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.

CRONSPMO
Market Cap
$1.03B
Sector
HealthBroad Market / Factor
52-Week High
$3.27$161.66
52-Week Low
$1.95$107.84
Enterprise Value
$211.19M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.

Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.

Invesco S&P 500 Momentum ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Invesco S&P 500 Momentum ETF

SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.

Read more on SPMO